Russell, James A.
Article History
Received: 19 July 2019
Accepted: 24 September 2019
First Online: 23 October 2019
Compliance with ethical standards
:
: Dr. Russell reports patents owned by the University of British Columbia (UBC) that are related to the use of PCSK9 inhibitor(s) in sepsis and related to the use of vasopressin in septic shock. Dr. Russell is an inventor on these patents. Dr. Russell was a founder, Director and shareholder in Cyon Therapeutics Inc. Dr. Russell is a shareholder in Molecular You Corp.Dr. Russell reports receiving consulting fees in the past 3 years from: (1) Asahi Kesai Pharmaceuticals of America (AKPA) (developing recombinant thrombomodulin in sepsis). (2) SIB Therapeutics LLC (developing a sepsis drug). (3) Ferring Pharmaceuticals (manufactures vasopressin and developing selepressin). No longer actively consulting for the following: (4) La Jolla Pharmaceuticals (developing angiotensin II; Dr. Russell chaired the DSMB of a trial of angiotensin II from 2015 to 2017)—no longer actively consulting. (5) Grifols (sells albumin)—no longer actively consulting. PAR Pharma (sells prepared bags of vasopressin)—no longer actively consulting.Dr. Russell reports having received an investigator-initiated grant from Grifols (entitled “Is HBP a mechanism of albumin’s efficacy in human septic shock?”) that was provided to and administered by UBC.
Free to read: This content has been made available to all.